MarketPeel
Insider Trading Intelligence
LV

Latha Vairavan

ARQT
SVP CHIEF FINANCIAL OFFICER · ARCUTIS BIOTHERAPEUTICS, INC. · CIK 0002065881
FILING MIX · LIFETIME36%/64%
BUYS
4
SELLS
7
TOTAL VALUE
$149.8K
COMPANIES
1
ACTIVE SINCE
May 2025
HOLDINGS NOW
85,978
AVG SELL PX
$24.45
TRADE KIND
SHOWING 11 / 11
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
7 backtested trades · 8 horizons · 22 pending
Forward-return performance of every backtestable P/S trade by Latha Vairavan, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d7+57.14%-2.29%+0.18%-2.47%-3.02%
14d7+57.14%-0.99%-0.69%-0.28%+0.16%
30d7+57.14%+2.64%-1.46%+5.98%+4.74%
60d7(1 pending)+50.00%+7.54%+2.34%+5.20%+2.13%
90d7(2 pending)+60.00%+7.80%+4.43%+17.46%+1.50%
180d7(5 pending)+50.00%+34.52%+7.55%+26.97%+26.97%
1y7(7 pending)
2y7(7 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ARQT · 85,978 shares · as of May 11, 2026
022,65245,30467,95590,6072026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2025
2025
2025
2026
2026
FLOW · 4 buys / 7 sellsCOVERAGE · 5 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
435$21.05$9.2K85,978May 11, 2026May 13, 2026View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,341$23.61$31.7K86,413May 4, 2026May 6, 2026View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,772$25.16$69.7K87,835Mar 2, 2026Mar 3, 2026View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
81$25.91$2.1K87,754Mar 2, 2026Mar 3, 2026View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
27,00090,607Feb 27, 2026Mar 3, 2026View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
70,00070,000Feb 27, 2026Mar 3, 2026View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,320$25.50$33.7K63,607Feb 2, 2026Feb 4, 2026View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
88$24.72$2.2K64,927Nov 3, 2025Nov 5, 2025View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
89$14.33$1.3K65,015Aug 4, 2025Aug 5, 2025View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
60,00060,000May 6, 2025May 7, 2025View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,00065,104May 6, 2025May 7, 2025View →
Other insiders · ARQT
Loading peer insiders…
About this filer
CIK 0002065881
ROLE
SVP Chief Financial Officer
PRIMARY
ARQT
COMPANIES
1
ACTIVE SINCE
May 2025
MARKETPEEL · /INSIDER/0002065881DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback